Legal Representation
Attorney
William R. Samuels
USPTO Deadlines
Application History
11 events| Date | Code | Type | Description | Documents |
|---|---|---|---|---|
| Jun 3, 2025 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | Loading... |
| Jun 3, 2025 | PUBO | A | PUBLISHED FOR OPPOSITION | Loading... |
| May 28, 2025 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | Loading... |
| May 6, 2025 | CNSA | P | APPROVED FOR PUB - PRINCIPAL REGISTER | Loading... |
| May 1, 2025 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
| Apr 30, 2025 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | Loading... |
| Apr 30, 2025 | MDSC | E | NOTICE OF DESIGN SEARCH CODE E-MAILED | Loading... |
| Dec 12, 2024 | ARAA | I | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | Loading... |
| Dec 12, 2024 | TCCA | I | TEAS CHANGE OF CORRESPONDENCE RECEIVED | Loading... |
| Dec 12, 2024 | REAP | I | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | Loading... |
| Nov 1, 2024 | NWAP | I | NEW APPLICATION ENTERED | Loading... |
Detailed Classifications
Class 005
Biological preparations for medical use in the treatment of genetic diseases and disorders, and central nervous system (CNS) disorders, namely, neurodegenerative disorders; pharmaceutical preparations, namely, recombinant adeno-associated viral (rAAV) vectors for use in gene therapy; Pharmaceutical preparations for the treatment of genetic diseases and disorders and central nervous system (CNS) disorders, namely, neurodegenerative disorders; Pharmaceutical preparations for use in gene therapy; Clinical medical reagents for use in gene therapy; Pharmaceutical preparations for the treatment of genetic disorders and neurodegenerative disorders; Therapeutic pharmaceutical compositions that include recombinant adeno-associated viral (rAAV) vectors to provide a platform for specific expression of biologics with therapeutic effect in gene therapy; Pharmaceutical preparations containing adeno-associated viral (AAV) vectors and nucleic acids for a system delivering genes to biological cells for use in the treatment of diseases, sicknesses, and disorders, namely, lysosomal storage disorders; gene therapy preparation for medical use containing genetic materials for sustained protein expression, namely, lysosomal enzyme expression
Additional Information
Design Mark
The mark consists of a half sun in the color orange with two lines extending outward. One line is blue, and the other is green.
Color Claim
The color(s) orange, blue, and green is/are claimed as a feature of the mark.
Classification
International Classes
005